BeOne Medicines Receives EMA PRIME Designation for BTK Degrader BGB-16673 in Waldenström's Macroglobulinemia
Key Insights
BeOne Medicines (search) received PRIME designation from the European Medicines Agency (search) for BGB-16673, an investigational BTK (search) degrader for treating Waldenström's macroglobulinemia (search) patients previously treated with BTK inhibitors.
The EMA's Committee for Medicinal Products for Human Use issued a positive opinion on the EU Orphan Drug Designation application for BGB-16673 in WM, with a final decision expected in the coming weeks.
BGB-16673 is designed to overcome resistance by degrading both wild-type and mutant forms of BTK (search), representing the most advanced BTK protein degrader currently in clinical development.
BeOne Medicines (search) announced that the European Medicines Agency (search) (EMA) has granted PRIority MEdicines (PRIME) designation to BGB-16673, the company's investigational Bruton's tyrosine kinase (search) (BTK (search)) degrader, for treating patients with Waldenström's macroglobulinemia (search) (WM) who have previously received BTK inhibitor therapy. This marks BeOne's first PRIME designation, representing a significant regulatory milestone for the global oncology company.
Regulatory Recognition for Novel Mechanism
The EMA's Committee for Medicinal Products for Human Use (CHMP) granted PRIME designation based on data demonstrating BGB-16673's novel mechanism and anti-tumor activity in B-cell malignancies (search). The CHMP recognized the limited treatment options available for WM patients following BTK (search) inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting.
"This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673," said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. "PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenström's macroglobulinemia (search)."
Additional Regulatory Designations
Beyond the PRIME designation, the EMA's CHMP issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM, with a final decision anticipated in the coming weeks. The regulatory recognition extends to the United States, where the FDA has granted Fast Track Designation to BGB-16673 for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (search) or small lymphocytic lymphoma (search) (CLL/SLL), and adult patients with relapsed or refractory mantle cell lymphoma (search) (MCL).
Innovative BTK Degradation Technology
BGB-16673 represents an orally available BTK (search) targeting protein degrader developed from BeOne's chimeric degradation activation compound (CDAC) platform. The drug is designed to promote the degradation of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients experiencing progressive disease. According to BeOne, BGB-16673 is the most advanced BTK protein degrader in clinical development, supported by an extensive global clinical development program.
PRIME Initiative Benefits
The EMA's PRIME initiative, launched in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. The program is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster. For BeOne, this designation enables enhanced interaction with the EMA throughout the development process, potentially streamlining the path to marketing authorization.